CA2462646A1 - Compositions de meningocoque assorties d'un adjuvant - Google Patents

Compositions de meningocoque assorties d'un adjuvant Download PDF

Info

Publication number
CA2462646A1
CA2462646A1 CA002462646A CA2462646A CA2462646A1 CA 2462646 A1 CA2462646 A1 CA 2462646A1 CA 002462646 A CA002462646 A CA 002462646A CA 2462646 A CA2462646 A CA 2462646A CA 2462646 A1 CA2462646 A1 CA 2462646A1
Authority
CA
Canada
Prior art keywords
composition
antigen
plg
protein
cpg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002462646A
Other languages
English (en)
Other versions
CA2462646C (fr
Inventor
Derek O'hagan
Nicholas Valiante
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2002/010869 external-priority patent/WO2002080648A2/fr
Application filed by Individual filed Critical Individual
Publication of CA2462646A1 publication Critical patent/CA2462646A1/fr
Application granted granted Critical
Publication of CA2462646C publication Critical patent/CA2462646C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

L'invention concerne une combinaison d'oligonucléotides CpG et de microparticules polymères qui constitue un adjuvant extrêmement efficace pour des antigènes de Neisseria. L'invention concerne donc une composition comprenant (a) un antigène de Neisseria; (b) un oligonucléotide CpG; et (c) une microparticule polymère biodégradable.
CA2462646A 2001-10-03 2002-10-03 Compositions de meningocoque assorties d'un adjuvant Expired - Fee Related CA2462646C (fr)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US32692901P 2001-10-03 2001-10-03
US60/326,929 2001-10-03
USPCT/US02/10869 2002-04-05
PCT/US2002/010869 WO2002080648A2 (fr) 2001-04-05 2002-04-05 Augmentation de l'immunite des muqueuses a la suite d'un amorçage parenteral
US37354702P 2002-04-17 2002-04-17
US60/373,547 2002-04-17
US38067702P 2002-05-13 2002-05-13
US60/380,677 2002-05-13
US25443802A 2002-09-24 2002-09-24
USPCT/US02/30423 2002-09-24
US10/254,438 2002-09-24
US0230423 2002-09-24
US10/265,083 2002-10-03
USPCT/US02/31486 2002-10-03
PCT/US2002/031726 WO2003028661A2 (fr) 2001-10-03 2002-10-03 Compositions de meningocoque assorties d'un adjuvant

Publications (2)

Publication Number Publication Date
CA2462646A1 true CA2462646A1 (fr) 2003-04-10
CA2462646C CA2462646C (fr) 2013-02-12

Family

ID=32601151

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2462646A Expired - Fee Related CA2462646C (fr) 2001-10-03 2002-10-03 Compositions de meningocoque assorties d'un adjuvant

Country Status (8)

Country Link
EP (1) EP1438323A4 (fr)
JP (1) JP4522699B2 (fr)
CN (1) CN100354297C (fr)
AU (1) AU2002334844B2 (fr)
BR (1) BR0213119A (fr)
CA (1) CA2462646C (fr)
NZ (1) NZ532274A (fr)
WO (1) WO2003028661A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
MXPA04011249A (es) * 2002-05-14 2005-06-06 Chiron Srl Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
SI2255826T1 (sl) * 2002-08-02 2016-07-29 Glaxosmithkline Biologicals S.A. Neisserijski vakcinski sestavki, ki obsegajo kombinacijo antigenov
US8034378B2 (en) 2002-12-27 2011-10-11 Novartis Vaccines And Diagnostics, Inc Immunogenic compositions containing phospholipid
ATE426412T1 (de) * 2003-01-30 2009-04-15 Novartis Vaccines & Diagnostic Adjuvante influenza-vakzine
ES2411080T3 (es) 2003-01-30 2013-07-04 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
JP5557415B2 (ja) 2003-06-02 2014-07-23 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 吸着させたトキソイドおよび多糖類含有抗原を含む微粒子に基づく免疫原性組成物
JP2007523173A (ja) * 2004-02-20 2007-08-16 イデラ ファーマシューティカルズ インコーポレイテッド 修飾免疫調節オリゴヌクレオチドにより誘導された強力な粘膜免疫応答
CA2588089C (fr) * 2004-11-15 2015-06-23 Novartis Vaccines And Diagnostics Inc. Compositions immunogenes contenant un antigene de l'anthrax, des microparticules de polymeres biodegradables, et un adjuvant immunologique contenant un polynucleotide
WO2006081576A2 (fr) 2005-01-28 2006-08-03 Galenbio, Inc. Compositions actives immunologiquement
ATE438385T1 (de) * 2005-03-02 2009-08-15 Secr Defence Pharmazeutische zusammensetzung
EP3067048B1 (fr) 2007-12-07 2018-02-14 GlaxoSmithKline Biologicals SA Compositions d'induction des réponses immunitaires
CN101559225B (zh) * 2008-04-18 2012-07-11 北京生物制品研究所 脑膜炎球菌疫苗
PL2863942T3 (pl) * 2012-06-21 2019-12-31 Northwestern University Cząstki sprzężone z peptydem

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CA2671261A1 (fr) * 1997-11-06 1999-05-20 Novartis Vaccines And Diagnostics S.R.L. Antigenes de neisseria
BR9906927A (pt) * 1998-01-14 2001-11-20 Chiron Spa Proteìnas de neisseria meningitidis
NZ541361A (en) * 1998-05-01 2008-04-30 Inst Genomic Research Neisseria meningitidis antigens and compositions relating to SEQ ID Nos:2916, 2918 and 2920
JP4601168B2 (ja) * 1998-07-29 2010-12-22 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 吸着表面を有する微小粒子、それを作製する方法、およびその使用
EP1144998A3 (fr) * 1998-10-09 2002-08-07 Chiron Corporation Sequences genomiques de neisseria et procedes d'utilisation
AU2457100A (en) * 1999-02-26 2000-09-14 Chiron S.P.A. Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs
AU2875700A (en) * 1999-02-26 2000-09-14 Chiron Corporation Microemulsions with adsorbed macromoelecules and microparticles
MXPA01010924A (es) * 1999-04-30 2002-05-06 Chiron Spa Antigenos de neisseria conservados.
BR0108711A (pt) * 2000-02-28 2004-06-22 Chiron Spa Expressão heteróloga de proteìnas de neisseria

Also Published As

Publication number Publication date
JP4522699B2 (ja) 2010-08-11
BR0213119A (pt) 2004-12-28
EP1438323A2 (fr) 2004-07-21
CA2462646C (fr) 2013-02-12
JP2005526697A (ja) 2005-09-08
AU2002334844B8 (en) 2003-04-14
WO2003028661A3 (fr) 2003-10-09
AU2002334844B2 (en) 2007-08-02
CN1599746A (zh) 2005-03-23
CN100354297C (zh) 2007-12-12
WO2003028661A2 (fr) 2003-04-10
NZ532274A (en) 2006-02-24
EP1438323A4 (fr) 2007-08-01

Similar Documents

Publication Publication Date Title
USRE45137E1 (en) Adjuvanted meningococcus compositions
CA2452720C (fr) Vaccins comprenant des adjuvants aluminium et histidine
US7348006B2 (en) Vaccines comprising aluminium adjuvants and histidine
RU2528066C2 (ru) Вакцины на основе солюбилизированных и комбинированных капсулярных полисахаридов
EP1587538B1 (fr) Vaccins contre le meningocoque administres par la muqueuse
JP5670003B2 (ja) 血清型ＢおよびＣ由来のＮｅｉｓｓｅｒｉａｍｅｎｉｎｇｉｔｉｄｉｓ抗原、ならびにさらなる抗原を含む組成物
AU2002330681A1 (en) Vaccines comprising aluminium adjuvants and histidine
US20110150923A1 (en) Mucosal meningococcal vaccines
CA2462646C (fr) Compositions de meningocoque assorties d'un adjuvant
AU2002334844A1 (en) Adjuvanted meningococcus compositions
US7838015B2 (en) Adjuvanted meningococcus compositions
AU2007231677A1 (en) Adjuvanted meningococcus compositions
MXPA04003186A (es) Composiciones de meningococo coadyuvantes.
RU2360699C2 (ru) Композиции менингококковых вакцин с адъювантами

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20141003